TALKDESK
16.12.2021 11:02:14 CET | Business Wire | Press release
Talkdesk®, Inc. , the global customer experience leader for customer-obsessed companies, has been chosen by Travelopia , the world’s largest collection of specialist travel brands, as its contact centre solution provider. Talkdesk provided a flexible, scalable solution as this pioneer in specialty travel charted a new course to remote call center technology for its portfolio of independent brands operating across the globe.
Travelopia - the only travel brand of its kind in the world - is at the forefront of global travel for those wanting a distinctive experience. With primary headquarters in Crawley, England, the company supports a global network of hospitality professionals representing 23 independent travel brands offering more than 70 destinations, spanning 10 countries across all seven continents. The Travelopia portfolio is exclusively focused on specialist travel, and the company strives to deliver unique experiences - from exploring Canada’s Rideau Canal by boat to joining the ranks of those rare travellers who cross the Antarctic Circle to see the South Pole. Whether travelling around the world by private jet or exploring closer to home on bicycle, Travelopia helps cultivate the passions and interests of its more than 750,000 guests each year.
Talkdesk CX Cloud™ , an end-to-end customer experience solution, made the transition from on premises to remote contact centre operations much easier for the geographically diverse Travelopia network of sales agents responsible for helping guests with highly customised travel itineraries and complex customer support enquiries. Agents across multiple geographies could better manage their time, which reduced the number of missed guest calls. The Talkdesk solution offered robust analytics, and those deeper insights into customer data enabled agents to proactively suggest new, customised travel experiences for returning guests. The flexibility and scalability of remote contact centre operations allowed Travelopia to efficiently adapt to the rapidly changing travel market conditions over the last year, as well as lowered operating costs during a volatile time for the travel industry as a whole.
“One of the core values driving Travelopia forward is our constant pursuit of the ultimate customer experience for our guests to enrich their lives through travel. As part of that pursuit, we’re committed to reflect on and evolve our operational approach,” said Mark Beauchamp, technology director, Travelopia. “For our move to remote contact centre operations, we wanted an innovative, flexible solution with the best tools to delight our customers. The Talkdesk solution provides our global network of agents across the portfolio of Travelopia brands with the resources they need to provide a seamless customer journey for guests - from first contact with our sales team through to the conclusion of that world beating travel experience.”
“Customer experience has never been more important to the success of travel and hospitality brands as it is now. Travellers worldwide are making up for lost time and missed opportunities, and they will choose to partner with those companies that can deliver not only that once-in-a-lifetime adventure, but also an unforgettable customer service experience before, during, and after,” said Kieran King, chief customer officer, Talkdesk. “With the Talkdesk solution, Travelopia agents can provide customer experience as unique and meaningful as the extraordinary travel experiences they create. We’re proud to partner with Travelopia in achieving their customer experience goals.”
Additional Resources
- See Talkdesk recognized as a Leader in the Gartner 2020 Magic Quadrant for Contact Center as a Service
- Hear from customers about why they selected Talkdesk CX Cloud and the difference it has made in their contact centers
Social Networks
- Web: https://www.talkdesk.com/customer-community/
- Blog: https://www.talkdesk.com/blog/
- Twitter: https://twitter.com/Talkdesk
- LinkedIn: https://www.linkedin.com/company/talkdesk/
- Facebook: https://www.facebook.com/Talkdesk/
- Instagram: https://www.instagram.com/Talkdesk/
About Talkdesk
Talkdesk® is a global cloud contact center leader for customer-obsessed companies. We believe that better customer experiences start with AI. Our automation-first customer experience solutions optimize our customers’ most critical customer service processes. Our speed of innovation, deep vertical expertise, and global footprint reflect our commitment to ensuring that businesses everywhere can deliver better customer experiences across any industry and through any channel, resulting in higher customer satisfaction and accelerated business outcomes. Over 1,800 innovative companies around the world, including Acxiom, Fujitsu, Hunter Douglas, IBM, Trivago, Tuft & Needle, YMCA, and 2U partner with Talkdesk to deliver a better way to great customer experience. Learn more and request a demo at www.talkdesk.com .
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered ® trademarks of their respective holders. Use of them does not imply any affiliation or endorsement by them.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom